-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents - PubMed - 8 month(s) ago
The treatment landscape of relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) has evolved significantly over the past decade after the approval of brentuximab vedotin (BV) and the programmed death-1 (PD-1) inhibitors. We evaluated how outcomes and practice patterns have changed for patients wi …
Source: pubmed.ncbi.nlm.nih.govCategories: Latest Headlines, Oncologists1Tweet-
SCI member Sally Arai, et al., found that overall survival for relapsed/refractory #HodgkinLymphoma after autologous HCT has improved following approval of #BrentuximabVedotin and PD-1 inhibitors. https://t.co/VedDG3e8a8 https://t.co/sPfZK5wYWe
-
-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Nivolumab plus #chemotherapy reduced the risk of disease progression and disease-related death compared to standard treatment with brentuximab plus chemotherapy in patients with previously untreated Stage III or IV classical #Hodgkinlymphoma (cHL). https://t.co/wzvYN6iFqx https://t.co/oOQ7kHXVcF
-
-
Mashup Score: 0Hodgkin Lymphoma Treatment Shifts to Immunotherapy : Oncology Times - 8 month(s) ago
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A study revealed 86.5% of patients with relapsed or refractory classic #Hodgkinlymphoma had a complete metabolic response when pembrolizumab was added to ifosfamide, carboplatin, and etoposide (ICE) #chemotherapy. Read more: https://t.co/FIPIhYpdq5 https://t.co/6CzPsVby8G
-
-
Mashup Score: 1Current Issue : Oncology Times - 8 month(s) ago
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care professionals. Learn more about our award-winning journal!
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New Issue Out Now! The September 5th issue features: #HodgkinLymphoma Treatment Shifts to Immunotherapy, Biological Aging Accelerated by Radiation Treatment in #BreastCancer, and more: https://t.co/pJq68H8b1y #CancerResearch https://t.co/nydGHF2fhN
-
-
Mashup Score: 0Updates in Lymphoma [2023] Interview - Elizabeth Brem, MD - MOASC - 8 month(s) ago
Elizabeth Brem , MD discusses the design and outcomes of the study referred to as 1826. The study aimed to enhance outcomes and address toxicities in Hodgkin lymphoma treatment. Nivolumab’s potential benefits in comparison to brentuximab within the AVD backbone were explored. Additionally, Brem highlights the collab…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🔬 Elizabeth Brem, MD (@DrLizBrem) advances Hodgkin lymphoma treatment with Study 1826: Nivolumab vs. Brentuximab in AVD. Collaboration shines! 🤝 @ASCO @MOASC_Office @UCIrvine @UCIrvineHealth 📽️ Watch the [video]https://t.co/2AvgdDvsbV #HodgkinLymphoma https://t.co/caWHzznISN
-
-
Mashup Score: 4Hodgkin Lymphoma - Cancer Stat Facts - 8 month(s) ago
Hodgkin Lymphoma statistics
Source: seer.cancer.govCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#HodgkinLymphoma is most frequently diagnosed among people between 20-34 years. The median age of diagnosis is 39. Visit our Cancer Stat Facts sheet to learn more: https://t.co/jSoS2m4bCq https://t.co/CnHAqK1hZS
-
-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Hodgkin lymphoma patients treated with nivolumab and AVD chemotherapy had a significantly lower risk of cancer progression than those treated with brentuximab vedotin and AVD a year after starting treatment. https://t.co/APUmMwVDj8 #Hodgkinlymphoma https://t.co/7PdwbsmV0l
-
-
Mashup Score: 0Hodgkin Lymphoma - Cancer Stat Facts - 9 month(s) ago
Hodgkin Lymphoma statistics
Source: seer.cancer.govCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#HodgkinLymphoma is most frequently diagnosed among people between 20-34 years. The median age of diagnosis is 39. Visit our Cancer Stat Facts sheet to learn more: https://t.co/9L6h7VgNUG https://t.co/UbrPfontiE
-
-
Mashup Score: 3How Blood Cancer Manipulates Immune Cells to Survive : Oncology Times - 10 month(s) ago
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The most comprehensive study to date of #Hodgkinlymphoma has provided fascinating insights into what tumor cells must do to survive. Researchers found that #cancercells use signals to attract certain types of immune cells and instruct them not to attack. https://t.co/hq0Vgv70aq https://t.co/sDD0HINFzc
-
After a median 1-year follow-up of Stage III or IV classical #Hodgkinlymphoma, progression-free survival with nivolumab plus #chemotherapy was 94% versus 86% for the brentuximab plus chemotherapy. https://t.co/0XtFxkkykP https://t.co/4xn9Vhh8Wk